Clinical analysis of the second-line treatment with lenvatinib plus camrelizumab in 12 cases of advanced intrahepatic cholangiocarcinoma
10.3760/cma.j.cn113884-20230909-00067
- VernacularTitle:仑伐替尼联合卡瑞利珠单抗二线治疗晚期肝内胆管癌12例分析
- Author:
Jiankang ZHANG
1
;
Yi LIU
;
Dong DING
;
Zhihuai WANG
;
Yuhang SHEN
;
Qingyu SUN
;
Bin NIE
;
Chunfu ZHU
;
Xihu QIN
;
Yuan GAO
Author Information
1. 南京医科大学附属常州第二人民医院肝胆胰外科 肝胆胰疾病研究所，常州 213000
- Keywords:
Biliary tract neoplasms;
Molecular targeted therapy;
Immunotherapy;
Efficacy
- From:
Chinese Journal of Hepatobiliary Surgery
2024;30(3):171-174
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of lenvatinib combined with camrelizumab as the second-line treatment for advanced intrahepatic cholangiocarcinoma (ICC).Methods:The clinical data of patients with advanced ICC undergoing the second-line treatment of lenvatinib combined with camrelizumab in the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University from June 2021 to June 2022 were screened and analyzed. A total of 12 patients were enrolled, including seven males and five females, aged (67.5±8.6) years. Response evaluation criteria in solid tumor 1.1 was used to evaluate the efficacy of treatment. The safety assessment adopts the Adverse Event Evaluation Standard 5.0. Kaplan-Meier method was conducted to plot survival curves.Results:Among the 12 patients (after 1-7 cycles of immune and targeted therapy), three achieved partial response, four achieved stable disease, and five were defined as progression disease. Adverse events of different degrees occurred in seven cases, among which three patients had adverse events of grade ≥ 3: one with hypertension, which was managed after antihypertensive and symptomatic treatment; one with elevated serum total bilirubin, which was improved after reducing the dose of lenvatinib; one with liver dysfunction, which was considered as immune-related liver toxicity and alleviated after discontinuing camrelizumab. The 1-month, 3-month, and 6-month survival rates and progression-free survival rates of the patients were 100.0%, 91.7%, 66.7%, and 83.3%, 41.7%, and 25.0%, respectively. The median overall survival of patients was 14.7 months (95% CI: 9.2-21.2) and the median time to progression was 8.0 months (95% CI: 4.1-11.9). Conclusion:Combination of lenvatinib and camrelizumab could bring survival benefits with controllable adverse events as the second-line treatment of patients with advanced ICC.
